Effectiveness and tolerability of pregabalin in patients with generalized anxiety disorders in routine clinical care;Wirksamkeit und verträglichkeit von pregabalin bei patienten mit generalisierten angststörungen in der täglichen praxis

Psychopharmakotherapie

Volumn 16, Issue 5, 2009, Pages 211-217

  Möller, Hans Jürgen ^b   Brasser, Matthias ^a   Kasper, Siegfried ^c   Volz, Hans Peter ^d   Boerner, Reinhard J ^e   Bandelow, Borwin ^f  

^a PFIZER INC   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Krankenhaus fur Psychiatrie   (Germany)

^e Gastroenterology General Internal Medicine and Infectious Diseases   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Flexible dosing; Generalized anxiety disorder; Non interventional study; Outpatient treatment; Pregabalin

Indexed keywords

PREGABALIN;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 70349929043     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Arbeitsgruppe Epidemiologische Methoden der Deutschen Arbeitsgemeinschaft Epidemiologie (DAE). Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Internet: http://www.gmds.de/texte/onlinedocs/ empfehlungen/empf-gep-langfassung.htm. (Zugriff am 11. Mai 2009).
2. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-596
3. Bandelow B, Zohar J, Hollander E, Kasper S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
4. Bian F, Li Z, Offord J, Davis MD, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type I genetically modified mice. Brain Res 2006;1075:68-80.
5. Brasser M. Pregabalin GAD-treatment in different patient populations under clinical practice conditions [P01-134]. Poster presentation at 17th EPA Congress, Lisbon, Portugal, January 2009. Eur Psychiatry 2009;24:S522.
6. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln - Empfehlungen zur Planung und Durchfuhrung von Anwendungsbeobachtungen vom 12. November 1998. Internet: http://www.bfarm.de/nn-424278/DE/Arzneimittel/zul/ bekanntm/zul-bekanntm-node.html-nnn=true. (Zugriff am 18. September 2008).
7. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001;13:78-88.
8. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Kurzleitlinie Angsterkrankungen. In: Praxisleitlinien in Psychiatrie und Psychotherapie, Band 2: Leitlinien zur Diagnostik und Therapie von Angsterkrankungen. Darmstadt: Steinkopff, 2000.
9. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
10. Feltner D, Wittchen HU, Kavoussi R, Brock J, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18-28.
11. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9.
12. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36.
13. Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007;47:1074-86.
14. Guy W. Clinical global impressions. In: National Institute of Mental Health (ed.). ECDEU Assessment for psychopharmacology. 1. edition. Rockville, USA: National Institute of Mental Health, 1976:221-7.
15. Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, et al. Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv 2008;59:641-7.
16. Hays R, Stewart A. Sleep measures. In: Stewart A, Ware J (eds.). Measuring functioning and well-being: The Medical Outcomes Study approach. Durham, NC, USA: Duke University Press, 1992:235-59.
17. Herrmann C, Buss U. Vorstellung und Validierung einer deutschen Version der "Hospital Anxiety and Depression Scale" (HAD-Skala). Diagnostica 1994;40:143-54.
18. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25:72-90.
19. Kasper S, Herman B, Nivoli G, Van Ameringen M, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int J Clin Psychopharmacology 2009;24:87-96.
20. Kessler RC, Andrade LH, Bijl RV, Offord DR, et al. The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. Psychol Med 2002;32:1213-25.
21. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:19-39.
22. Lowe B, Decker O, Muller S, Brahler E, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008;46:266-74.
23. Mallison R, Tilke C, Brasser M, Pittrow D. Pregabalin bei Patienten mit neuropathischen Schmerzen. MMW Fortschr Med 2007;149:1-8.
24. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006;7:2139-54.
25. Montgomery SA, Tobias K, Zornberg GL, Kasper S, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006;67:771-82.
26. Neugebauer E. Evidenzbasierte Versorgungsforschung. Vortrag beim Deutschen Ärztekongress, Berlin, 20.7.2007.
27. Ormel J, Von Korff M, Ustun TB, Pini S, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. Jama 1994;272:1741-8.
28. Pajonk F, Holzbach R, Naber D. Aussagekraft offener Studien im Vergleich zu kontrollierten Studien in der Prüfung von Neuroleptika. Fortschr Neurol Psychiat 2000;68:313-20.
29. Pande AC, Crockatt JG, Feltner DE, Janney CA, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
30. Pande AC, Feltner DE, Jefferson JW, Davidson JR, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-9.
31. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, place-bo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005;25:151-8.
32. Rejas J, Ribera MV, Ruiz M, Masrramon X. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2006;11:329-40.
33. Rickels K, Pollack MH, Feltner DE, Lydiard RB, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30.
34. Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, et al. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord 1997;43:105-19.
35. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7.
36. Willich S. Pragmatische Ansätze erforderlich. Dtsch Ärztebl 2006;103:A2524-9.
37. Wittchen HU, Carter RM, Pfister H, Montgomery SA, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000;15:319-28.
38. Wittchen HU, Kessler RC, Beesdo K, Krause P, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34.